Hao‐Xiang Wu

2.1k total citations · 1 hit paper
38 papers, 1.3k citations indexed

About

Hao‐Xiang Wu is a scholar working on Oncology, Cancer Research and Molecular Biology. According to data from OpenAlex, Hao‐Xiang Wu has authored 38 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Oncology, 12 papers in Cancer Research and 9 papers in Molecular Biology. Recurrent topics in Hao‐Xiang Wu's work include Cancer Immunotherapy and Biomarkers (14 papers), Cancer Genomics and Diagnostics (10 papers) and Pancreatic and Hepatic Oncology Research (5 papers). Hao‐Xiang Wu is often cited by papers focused on Cancer Immunotherapy and Biomarkers (14 papers), Cancer Genomics and Diagnostics (10 papers) and Pancreatic and Hepatic Oncology Research (5 papers). Hao‐Xiang Wu collaborates with scholars based in China, United Kingdom and United States. Hao‐Xiang Wu's co-authors include Rui‐Hua Xu, Zixian Wang, Qi Zhao, Yun Wang, Min Wang, Hui Luo, Feng Wang, Yan‐Xing Chen, Zhao-Lei Zeng and Zhen Zhang and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Advanced Functional Materials.

In The Last Decade

Hao‐Xiang Wu

35 papers receiving 1.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Integrated analysis of single-cell and bulk RNA sequencing data reveals a pan-cancer stemness signature predicting immunotherapy response

2022 167 citations Zhen Zhang, Zixian Wang et al. Genome Medicine profile →

Peers

Countries citing papers authored by Hao‐Xiang Wu

Since Specialization

Citations

This map shows the geographic impact of Hao‐Xiang Wu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hao‐Xiang Wu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hao‐Xiang Wu more than expected).

Fields of papers citing papers by Hao‐Xiang Wu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hao‐Xiang Wu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hao‐Xiang Wu. The network helps show where Hao‐Xiang Wu may publish in the future.

Co-authorship network of co-authors of Hao‐Xiang Wu

This figure shows the co-authorship network connecting the top 25 collaborators of Hao‐Xiang Wu. A scholar is included among the top collaborators of Hao‐Xiang Wu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hao‐Xiang Wu. Hao‐Xiang Wu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Gradient Heterogeneous Coatings for Silicon‐Carbon Anodes in Lithium‐Ion Batteries 2025 ·Advanced Functional Materials ·(unknown), (unknown), (unknown), Tao Zhang, Xin‐Tao Wu, Peng Hu, (unknown), (unknown), Hao‐Xiang Wu, Yannan Zhang, Zhongren Zhou, Yingjie Zhang, Peng Dong	0
2	Nano-silver powder for photovoltaic silver paste: Synthesis, technical principles, and future perspectives 2025 ·Journal of Alloys and Compounds ·(unknown), (unknown), (unknown), Hao‐Xiang Wu, Xintao Wu, Yingjie Zhang, Peng Dong, Zhongren Zhou	0
3	Undifferentiated carcinoma with osteoclast-like giant cells of the pancreas: a narrative review 2024 ·Frontiers in Oncology ·Hao‐Xiang Wu	1
4	Modulator of TMB-associated immune infiltration (MOTIF) predicts immunotherapy response and guides combination therapy 2024 ·Science Bulletin ·(unknown), (unknown), Xuexin Li, Yan‐Xing Chen, Hao‐Xiang Wu, Zexian Liu, Martin Košař, Jiří Bártek, Zixian Wang, Rui‐Hua Xu	3
5	MFSD2A potentiates gastric cancer response to anti‐PD‐1 immunotherapy by reprogramming the tumor microenvironment to activate T cell response 2023 ·Cancer Communications ·Bin Zhang, (unknown), Hao‐Xiang Wu, Feng Wang, Yangyang Chai, Ye Hu, Bingjing Wang, Yu Zhou, (unknown), Rui‐Hua Xu, Xuetao Cao	22
6	Development of antibody‐drug conjugates in cancer: Overview and prospects 2023 ·Cancer Communications ·Dan‐Yun Ruan, Hao‐Xiang Wu, (unknown), Rui‐Hua Xu	39
7	Clinical Benefit of First-Line Programmed Death-1 Antibody Plus Chemotherapy in Low Programmed Cell Death Ligand 1–Expressing Esophageal Squamous Cell Carcinoma: A Post Hoc Analysis of JUPITER-06 and Meta-Analysis 2022 ·Journal of Clinical Oncology ·Hao‐Xiang Wu, (unknown), Ye He, Zixian Wang, Wen‐Long Guan, Yan‐Xing Chen, Yichen Yao, Ning‐Yi Shao, Rui‐Hua Xu, Feng Wang	35
8	Integrated analysis of single-cell and bulk RNA sequencing data reveals a pan-cancer stemness signature predicting immunotherapy response breakdown → 2022 ·Genome Medicine ·Zhen Zhang, Zixian Wang, Yan‐Xing Chen, Hao‐Xiang Wu, Ling Yin, Qi Zhao, Hui Luo, Zhao-Lei Zeng, Miao‐Zhen Qiu, Rui‐Hua Xu	167
9	Transplantation for EASL-CLIF and APASL acute-on-chronic liver failure (ACLF) patients: The TEA cohort to evaluate long-term post-Transplant outcomes 2022 ·EClinicalMedicine ·(unknown), (unknown), Zijie Zhang, (unknown), Huan Tong, (unknown), Hao‐Xiang Wu, Xiaosong Chen, Hanyong Sun, Jianjun Zhang, (unknown), Hao Feng, Qiang Xia	22
10	Two-Dimensional Shear Wave Elastography Evaluation of Post-transplantation Complications in Pediatric Receipt: A Retrospective Cohort 2022 ·Frontiers in Pediatrics ·Lihong Gu, (unknown), Hao‐Xiang Wu, Yuchen Hou, (unknown), Zhifeng Xi, Fang Hua, Hao Feng, Lixin Jiang, Qiang Xia	7
11	Advancing to the era of cancer immunotherapy 2021 ·Cancer Communications ·Yun Wang, Min Wang, Hao‐Xiang Wu, Rui‐Hua Xu	137
12	EPHA7 mutation as a predictive biomarker for immune checkpoint inhibitors in multiple cancers 2021 ·BMC Medicine ·Zhen Zhang, Hao‐Xiang Wu, (unknown), Zixian Wang, Lu-Ping Yang, Zhao-Lei Zeng, Hui Luo	27
13	Postoperative circulating tumor DNA as markers of recurrence risk in stages II to III colorectal cancer 2021 ·Journal of Hematology & Oncology ·Gong Chen, Junjie Peng, Qian Xiao, Hao‐Xiang Wu, Xiaojun Wu, Fulong Wang, Li Li, Peirong Ding, Qi Zhao, Yaqi Li, Da Wang, Yang Shao, Hua Bao, Zhizhong Pan, Kefeng Ding, Sanjun Cai, Feng Wang, Rui‐Hua Xu	107
14	Neoadjuvant Programmed Cell Death 1 (PD-1) Inhibitor Treatment in Patients With Hepatocellular Carcinoma Before Liver Transplant: A Cohort Study and Literature Review 2021 ·Frontiers in Immunology ·(unknown), Zijie Zhang, (unknown), Huan Tong, Zhifeng Xi, Hao‐Xiang Wu, Xiaosong Chen, Lei Xia, Hao Feng, Jianjun Zhang, Qiang Xia	60
15	Chrysophanol Alleviates Metabolic Syndrome by Activating the SIRT6/AMPK Signaling Pathway in Brown Adipocytes 2020 ·Oxidative Medicine and Cellular Longevity ·Xueying Liu, Zehong Yang, (unknown), Wen Luo, Wentao Duan, Junmei Zhang, (unknown), Min Liu, (unknown), (unknown), Hao‐Xiang Wu, Shaoxiang Xian, Meijing Liu, Changhui Liu, Chuangpeng Shen	22
16	KMT2A/C mutations function as a potential predictive biomarker for immunotherapy in solid tumors 2020 ·Biomarker Research ·Rui Zhang, Hao‐Xiang Wu, (unknown), Xiaoyan Xie	13
17	<p>A real-world evidence of efficacy of palliative gastrectomy plus chemotherapy in metastatic gastric cancer patients</p> 2019 ·Cancer Management and Research ·Lu-Ping Yang, Zixian Wang, Ming-Ming He, Hao‐Xiang Wu, Shuqiang Yuan, Wei Wang, Ying Jin, Chao Ren, Zhi‐Qiang Wang, Feng‐Hua Wang, Yuhong Li, Feng Wang, Rui‐Hua Xu	7
18	Appraisal of Prognostic Interaction between Sidedness and Mucinous Histology in Colon Cancer: A Population-Based Study Using Inverse Probability Propensity Score Weighting 2019 ·Journal of Cancer ·Zixian Wang, (unknown), Hao‐Xiang Wu, (unknown), Pei-Rong Ding, Dan Xie, Gong Chen, Yuhong Li, Feng Wang, Rui‐Hua Xu	4
19	Alteration of liver glycopatterns during cirrhosis and tumor progression induced by HBV 2016 ·Glycoconjugate Journal ·Yannan Qin, Yaogang Zhong, Tianran Ma, Fei Wu, Hao‐Xiang Wu, Hanjie Yu, Chen Huang, Zheng Li	17
20	Avian Influenza Virus Infection Risk in Humans with Chronic Diseases 2015 ·Scientific Reports ·Yaogang Zhong, Yannan Qin, Hanjie Yu, Jingmin Yu, Hao‐Xiang Wu, Lin Chen, Peixin Zhang, Xiurong Wang, Zhansheng Jia, Yonghong Guo, Hua Zhang, Junjie Shan, Yuxia Wang, Hailong Xie, Xiaojie Li, Zheng Li	37

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact